Harvard Apparatus achieved considerable buzz this morning in
announcing significant results from animal research on its second-generation
bioengineered platform. Demonstrating clear evidence of complete esophageal
tissue regeneration within two weeks, the study “far exceeded” company – and
market, so it seems – expectations.
“We pursued these animal studies to test the design and
technology enhancements we have made to our second generation technology and to
prepare us for our upcoming studies with the Mayo Clinic. We are very
encouraged by the results of these studies and by the significant advancements
we have made across all three indications …,” HART CEO Jim McGorry said in
today’s news release.
Company chief Medical Officer Saverio La Francesca, M.D.
added to the sentiment, stating that “We believe that our second generation
implant possesses all the necessary cues to elicit full regeneration of the
esophagus. Importantly, our esophageal implant addresses a very significant
need as a potentially life-saving treatment for patients with esophageal
cancer. Each year in the U.S. approximately 17,000 new cases of esophageal
cancer are diagnosed, and more than 4,000 are addressed by surgery. Our results
underscore the value and potential of our platform technology to treat these
patients and pave the way for further studies and our regulatory pathway for
human clinical trials.”
McGorry has been at his executive post for four months now,
and moving forward will guide the company through expanded preclinical trials
at the Mayo Clinic slated for December. HART plans to file an initial IND
application with the USDA next year.
Today’s news boosted shares more than 115% in mid-day
trading, a welcome increase considering the company earlier this week received
a delisting notice from NASDAQ. The company’s stock is down 89% since the start
of the year.
If that’s enough to pique your interest, join in on the
company’s conference call at 5 p.m. ET today for a discussion of study results.
Dial toll-free 877-407-8293, or international: 201-689-8349, and reference
Harvard Apparatus Regenerative Technology, Inc. You can also access the audio
webcast at http://public.viavid.com/index.php?id=117087.
A replay will be available within approximately three hours
from the end of the call through 11:59 pm ET on November 19, 2015, and will be
accessible by dialing toll-free 877-660-6853, or toll/international
201-612-7415, and referencing conference ID “13624147.” The replay will also be
made available at the web link above and on the company’s web site,
www.harvardapparatusregen.com.
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
